News

circle_logo2

CalciMedica Announces Publication of Preclinical Data in Journal of Immunology Further Validating Calcium Release-Activated Calcium (CRAC) Channels as Drug Targets for Diseases of the Airways

Data provides further evidence of the broad potential for CRAC channel inhibitors to benefit patients across multiple disease areas involving the lungs LA JOLLA, Calif., …

CalciMedica Publishes Positive Data from Phase 2a Study of Auxora in Patients with Acute Pancreatitis and Announces First Patients Dosed in Phase 2b Study

Data from Phase 2a Study Demonstrated Patients Treated with Auxora Experienced Reduced Severity of Acute Pancreatitis, Less Persistent Systemic Inflammatory Response Syndrome (SIRS) and More …

CalciMedica Announces $21 Million Series D Financing

Round led by Quark Venture LP and Global Health Sciences (GHS) Fund Funds to support advancement of anti-inflammatory therapy, AuxoraTM, currently being evaluated in severe …

CalciMedica Presents New Clinical Data Demonstrating Improved D-Dimer Biomarker Levels with Auxora™ in Severe COVID-19 Pneumonia at the 50th Critical Care Congress

D-dimer levels have been correlated with disease severity and risk of mortality in patients with COVID-19 Treatment with Auxora improved D-dimer levels in patients with …

CalciMedica Announces IDMC Recommendation to Continue with Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia

LA JOLLA, Calif., December 17, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (“CRAC”) channels for the …

Scroll to Top